Palbo Capsule

Palbo Capsule 125 mg

Palbo Capsule 125 mg is a targeted therapy used to treat certain types of advanced breast cancer and other advanced cancers. It is a type of chemotherapy drug and is known as a type of inhibitor of the CDK4 and CDK6 molecules. This drug has been developed by Pfizer, Inc

Uses for

Palbo Capsule 125 mg is used to treat hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced or metastatic breast cancer in certain types of cancer patients. It is also used to treat certain types of non-small cell lung cancer (NSCLC), ovarian cancer, and colorectal cancer.

Brand Name	Palbo
Type	Capsule
Weight	125 mg
Generic	Palbociclib
Manufacturer	Drug International Ltd.
Available in	English বাংলা

Mechanism of Action

Palbo Capsule 125 mg works by inhibiting two molecules (cyclin-dependent kinases 4 and 6, or CDK4/6), which are proteins that are involved in the enlargement of cancer cells. By blocking these molecules, the drug helps to restrict the growth and spread of cancer cells. It also helps to reduce the amount of circulating cancer cells in the body.

How long does it take to work?

It is difficult to give an exact time frame for how long it takes the drug to work, as it may vary from patient to patient. Generally, it is expected that Palbo Capsule 125 mg will start to show improvement in certain patient groups after 8 to 10 weeks, based on clinical trials.

Absorption

Palbo Capsule 125 mg is well-absorbed when taken by mouth. It is expected to have a mean time to peak plasma concentration of 1.6 hours after oral administration.

Route of Elimination

Palbo Capsule 125 mg is eliminated from the body via the urine and feces. About 62% of the drug is eliminated through the urine and 37% through the feces in humans.

Dosage

The recommended dose of Palbociclib is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food. Patients should be encouraged to take their dose of Palbociclib at approximately the same time each day. For men treated with combination Palbociclib plus aromatase inhibitor therapy, consider treatment with an LHRH agonist according to current clinical practice standards.

Recommended Dose Modification for Adverse Reactions:

Recommended Starting Dose: 125 mg/day
First Dose Reduction: 100 mg/day
Second Dose Reduction: 75 mg/day

If further dose reduction below 75 mg/day is required, discontinue. Or, as directed by the registered physician.

Use in Children: Palbociclib is not indicated for use in children.

The standard dosage of Palbo Capsule 125 mg is 125 mg taken orally each day. Patients should not take more or less than this amount. It should be taken with food and a full glass of water. Dosage may be modified if the patient experiences side effects or if there are specific directions from their doctor.

Administration

Palbo Capsule 125 mg should be taken orally, with food and a full glass of water. The dose should be taken at the same time each day to ensure an even concentration in the blood. Do not crush or chew the tablets.

Side Effects

The most common side effects of Palbo Capsule 125 mg include fatigue, nausea, vomiting, diarrhea, decreased appetite, mouth sores, hair loss, and rash. Patients should also look out for more serious side effects like liver damage and low white blood cell count. Patients should speak to their healthcare provider if they experience any of these side effects.

Toxicity

When taken as directed, Palbo Capsule 125 mg is accepted as being safe and well-tolerated. However, overdosing can lead to a range of serious side effects and toxicity. Patients should speak to their healthcare provider immediately if they take an overdose.

Precautions

Patients should inform their healthcare provider if they are pregnant, plan to become pregnant, breastfeeding, or taking any other medications, including over-the-counter medications or supplements. Patients should also talk to their healthcare provider if they have any allergies, kidney or liver problems, and if they are having any type of surgery.

Interactions

Palbo Capsule 125 mg may interact negatively with some medications, including anticoagulants, digitalis, triazolam, and muscle relaxants. Patients should tell their healthcare providers about all medications they are taking before starting Palbo Capsule 125 mg.

Disease Interaction

Palbo Capsule 125 mg may interact with other diseases or conditions, including kidney or liver impairment, pregnant or breastfeeding women, and those taking anticoagulants. Patients with any of these conditions should speak to their healthcare provider before taking Palbo Capsule 125 mg.

Drug Interactions

Palbo Capsule 125 mg may interact with certain drugs and supplements, including anticoagulants, digitalis, triazolam, and muscle relaxants. Patients should always inform their healthcare provider about all medications they are taking before starting Palbo Capsule 125 mg.

Food Interactions

Palbo Capsule 125 mg should be taken with food and a full glass of water. It is important to avoid taking large amounts of any food or drinks that can inhibit the absorption of the drug, such as grapefruit juice or other products containing quinine derivatives.

Pregnancy Use

Palbo Capsule 125 mg is not recommended for use during pregnancy. It is not known whether Palbo Capsule 125 mg is present in the blood or if it can pass to the fetus. Patients should speak to their healthcare provider if they are pregnant or plan to become pregnant.

Lactation Use

It is not known whether Palbo Capsule 125 mg passes into human milk in significant amounts. Therefore, it is not recommended for use during lactation. Patients should consult with their healthcare provider first if they are nursing or plan to breastfeed.

Acute Overdose

The signs and symptoms of an acute overdose may include decreased blood pressure, difficulty breathing, increased heart rate, confusion, seizures, and coma. If an overdose is suspected, patients should seek immediate medical attention.

Contraindication

Palbo Capsule 125 mg is contraindicated in patients who are hypersensitive to any of its components or to any other active and/or inactive ingredients of the drug. In addition, the drug should not be administered to patients with severe hepatic impairment.

Use Direction

Patients should take Palbo Capsule 125 mg exactly as directed by their healthcare provider. This may include not only taking it orally, with food and a full glass of water, but also making sure to take it at the same time each day. The patient should not stop taking Palbo Capsule 125 mg, even if they feel better, and should not take more than the recommended dose.

Storage Condition

Palbo Capsule 125 mg should be stored at room temperature, away from moisture and direct light. Patients should avoid freezing or refrigerating the drug and should always keep it in the original container with the original label.

Volume of Distribution

The volume of distribution of Palbo Capsule 125 mg is higher in plasma than in other tissues. This volume is approximately 70 L in humans.

Half-Life

The plasma half-life of Palbo Capsule 125 mg is about 3 days. This amount is expected to reach steady state within 4 weeks of daily use.

Clearance

The clearance of this drug is approximately 6 L/hr, and it is primarily excreted in the feces. Approximately 80% of the Palbo Capsule 125 mg dose is eventually eliminated from the body.

See in details version Palbo Capsule 125 mg also Palbo Capsule 125 mg in bangla